Janney Montgomery Scott Resumes Supernus Pharmaceuticals (SUPN) at Buy
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Price: $43.29 -0.23%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 70
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 70
Join SI Premium – FREE
Janney Montgomery Scott analyst Irene Buhalo resumes coverage on Supernus Pharmaceuticals (NASDAQ: SUPN) with a Buy rating.
For an analyst ratings summary and ratings history on Supernus Pharmaceuticals click here. For more ratings news on Supernus Pharmaceuticals click here.
Shares of Supernus Pharmaceuticals closed at $37.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Starts Eupraxia Pharmaceuticals (EPRX) at Outperform
- Wells Fargo Starts Vertiv (VRT) at Overweight
- Wells Fargo Starts Johnson Controls (JCI) at Overweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
Janney Montgomery ScottSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
